Ariad Pharmaceuticals (NASDAQ:ARIA), a company whose shares are moving quickly, is trading 1.5% lower to $20.06. The Dow Jones Industrial Average is now trading 0.4% lower to 13,089 and the S&P is trading 0.6% lower to 1,418.
Over the past year, Ariad Pharmaceuticals has traded in a range of $11.60 to $25.40 and is now at $20.06, 73% above that low. In the last five trading sessions, the 50-day moving average (MA) has fallen 1.1% while the 200-day MA has risen 0.5%.
Ariad Pharmaceuticals has overhead space with shares priced $20.06, or 31.0% below the average consensus analyst price target of $29.06. Ariad Pharmaceuticals shares should encounter resistance at the 50-day moving average (MA) of $21.94 and support at its 200-day MA of $19.18.
ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.